Buscar
-
Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting
(Clinical Pharmacology and Therapeutics. vol. 103, n° 6, pp. 1038-1046, 2018-06)Article de revue -
Effectiveness and safety of standard and reduced doses of dabigatran versus rivaroxaban in non-valvular atrial fibrillation: A cohort study in the snds french nationwide claims database
(Value Health. vol. 21, pp. S7-S7, 2018-10)Article de revue -
Benefit-risk profile of dabigatran compared with vitamin-K antagonists in elderly patients with non-valvular atrial fibrillation: results from a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 822-822, 2018-08)Article de revue -
Benefit-risk of rivaroxaban 20 or 15mg compared to vitamin-K antagonists in patients with non-valvular atrial fibrillation: a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 1014-1014, 2018-08)Article de revue